Theratechnologies Inc Forecasted to Post FY2020 Earnings of $0.27 Per Share (TSE:TH)

Theratechnologies Inc (TSE:TH) – National Bank Financial dropped their FY2020 earnings estimates for shares of Theratechnologies in a report released on Tuesday, October 8th. National Bank Financial analyst E. Leno now expects that the company will post earnings per share of $0.27 for the year, down from their prior estimate of $0.30. National Bank Financial has a “Sector Perform” rating and a $7.00 price target on the stock.

Theratechnologies (TSE:TH) last released its earnings results on Thursday, July 11th. The company reported C($0.06) earnings per share (EPS) for the quarter. The company had revenue of C$20.92 million during the quarter, compared to analysts’ expectations of C$26.00 million.

A number of other research firms have also issued reports on TH. Mackie decreased their target price on Theratechnologies from C$8.15 to C$7.00 and set a “hold” rating for the company in a report on Friday, July 12th. Royal Bank of Canada decreased their target price on Theratechnologies from C$7.00 to C$6.00 and set a “sector perform” rating for the company in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Theratechnologies presently has a consensus rating of “Hold” and an average target price of C$8.75.

TSE:TH opened at C$4.90 on Thursday. The firm has a market cap of $387.84 million and a PE ratio of -55.06. The stock has a fifty day moving average price of C$5.35 and a 200 day moving average price of C$6.27. Theratechnologies has a 12-month low of C$4.71 and a 12-month high of C$9.74. The company has a current ratio of 2.51, a quick ratio of 1.94 and a debt-to-equity ratio of 167.71.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Recommended Story: Stock Symbol

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.